With the approval of esketamine hydrochloride and the application of an Atorvastatin patent, Supriya Lifescience broadens its worldwide reach.
- Supriya Lifescience is the first Indian business to be approved by ANVISA, Brazil’s health regulatory body, for Esketamine Hydrochloride.
- Supriya Lifescience has created a novel method for producing atorvastatin at a cheap cost. This medication is used globally as a primary therapy for lowering cholesterol and avoiding cardiovascular disease.
December 9, 2024, Mumbai: Leading the pharmaceutical sector globally, Supriya Lifescience Ltd., strengthened its position in foreign markets by achieving two noteworthy milestones. The business has received permission from ANVISA, Brazil’s health authorities. (Agência Nacional de Vigilância Sanitária), for Esketamine Hydrochloride, marking a significant advancement in the company’s product line expansion in Brazil and Latin America. The first company in Brazil to obtain regulatory approval for this extremely specialised medication is Supriya Lifescience.
Esketamine hydrochloride is an essential medication for the treatment of mental disorder and is anticipated to have a big effect on the LATAM market. This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing.
Additionally, the company filed a groundbreaking patent application for a more advanced, affordable atorvastatin manufacturing technique. This innovative method lowers production costs while improving medicine efficacy, making medications more accessible to patients. Atorvastatin, a crucial medication for lowering cholesterol and avoiding cardiovascular disease, is used extensively in global healthcare. This accomplishment demonstrates Supriya’s commitment to lowering medicine costs and improving accessibility.
“Our invention in the synthesis of atorvastatin demonstrates our commitment to transforming pharmaceutical manufacturing while maintaining affordability,” said Dr. Satish Wagh, Executive Chairman and Full-Time Director, Supriya Lifescience Ltd. The CADIFA certification enhances our worldwide reach and enables us to launch innovative treatments like esketamine hydrochloride in significant international nations, beginning with Brazil.
Supriya Lifescience is now prepared to enter the rapidly expanding LATAM market thanks to CADIFA permission. The business’s ongoing emphasis on innovation, regulations compliance, and its goal of ensuring that everyone has access to high-quality healthcare places it in a prominent position in the global pharmaceutical market.